Using of decapeptyl in IVF program

详细

The main purpose of this research to value the efficacy of the different schemes of superovulation stimulation in IVF program. The analysis of IVF efficacy was conducted to 200 matrimonial couples with infertility. The average age of patients was 32.5 years, the average duration of infertility — 8.5 years. The primary sterility was presented in 34,5% of patients, secondary — in 65,5%. The tubal-peritoneal sterility was in 58% of cases, endocrine — in 10%, associative — in 32%.

全文:

The main purpose of this research to value the efficacy of the different schemes of superovulation stimulation in IVF program. The analysis of IVF efficacy was conducted to 200 matrimonial couples with infertility. The average age of patients was 32.5 years, the average duration of infertility — 8.5 years. The primary sterility was presented in 34,5% of patients, secondary — in 65,5%. The tubal-peritoneal sterility was in 58% of cases, endocrine — in 10%, associative — in 32%. In dependence of the conducted scheme of superovulation stimulation the patients were divided on 3 groups identified on the age, duration and main causes of infertility. The 1 group was formed from the 122 patients received klomifen-citrat and HMG aimed to the induction of superovulation. In the second group (63 patients) the stimulation was conducted by the HMG after preliminary injection of Decapeptyl 3,75 mg (Beaufour-IPSEN International) by the long protocol. In 22 cases before subjecting of HMG preceded the daily injection of Decapeptyl 0,1 mg (3 group). The analysis showed that the number of the ripened follicles was higher by injection of Decapeptyl 3,75 mg (11,85+1,8) and Decapeptyl 0,1 mg (8,54+2,1) opposite to 6,6+1,3 in 1 group. The fertilization was accordingly in 70,2%, 71,1 % and 58,3% of cases. The transfer of embryos to one patient was in 1 group 2,9+0,1, in 2 group — 4,2+0,2, in 3 group — 3,6+0,3. The rate of pregnancy in 1 group composed 18%, in 2 — 27%, in 3 — 31%. Thus, the best results of IVF program were received in using of superovulation stimulation protocol including the agonists of gonadotrophin-relising hormone especially of daily form.